Latest news in cancer
Amivantamab-vmjw receives fast approval from the FDA for metastatic non-small cell lung cancer
August 2021: The FDA granted amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.), a bispecific antibody directed against epidermal growth factor (EGF) and MET...
Nivolumab has been approved by the FDA for resected esophageal or gastroesophageal junction cancer
August 2021: The FDA has approved Nivolumab (Opdivo, Bristol-Myers Squibb Company) for patients with fully resected oesophagus or gastroesophageal junction...
Pembrolizumab receives accelerated approval from the FDA for HER2-positive gastric cancer
August 2021: Pembrolizumab (Keytruda, Merck & Co.) in combination with trastuzumab, fluoropyrimidine-, and platinum-containing chemotherapy has been...
The FDA has granted loncastuximab tesirine-lpyl accelerated approval for large B-cell lymphoma
August 2021: The FDA granted loncastuximab tesirine-lpyl (Zynlonta, ADC Therapeutics SA), a CD19-directed antibody and alkylating agent conjugate, accelerated...
Dostarlimab-gxly receives accelerated approval from the FDA for dMMR endometrial cancer
August 2021: Dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) received accelerated approval from the Food and Drug Administration for adult patients with...
Nivolumab in addition to chemotherapy is approved by FDA for metastatic gastric cancer and esophageal adenocarcinoma
August 2021: For advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma, the Food and Drug Administration...
Sacituzumab govitecan receives fast approval from the FDA for advanced urothelial cancer
August 2021: Sacituzumab govitecan (Trodelvy, Immunomedics Inc.) was given accelerated approval by the Food and Drug Administration for patients with locally...
Sacituzumab govitecan receives FDA approval for triple-negative breast cancer
August 2021: Sacituzumab govitecan (Trodelvy, Immunomedics Inc.) gained regular FDA clearance for patients with unresectable locally advanced or metastatic...
The FDA has approved idecabtagene vicleucel for the treatment of multiple myeloma
August 2021: The Food and Drug Administration approved idecabtagene vicleucel (Abecma, Bristol Myers Squibb) for the treatment of adult patients with relapsed...
Pembrolizumab has been approved by the FDA for the treatment of esophageal or gastroesophageal junction cancer
August 2021: Pembrolizumab (Keytruda, Merck Sharp & Dohme Corp.) in combination with platinum and fluoropyrimidine-based chemotherapy has been approved by...
The FDA has approved relugolix for the treatment of advanced prostate cancer
August 2021: The first oral gonadotropin-releasing hormone (GnRH) receptor antagonist, relugolix (ORGOVYX, Myovant Sciences, Inc.), was approved by the Food...
Tivozanib has been approved by the FDA for the treatment of relapsed or refractory advanced renal cell carcinoma
August 2021: Tivozanib (Fotivda, AVEO Pharmaceuticals, Inc.), a kinase inhibitor, has been approved by the FDA for adult patients with relapsed or refractory...
Need help? Our team is ready to assist you.
We wish a speedy recovery of your dear and near one.